Uncategorized

Convert nonresponder insights into smarter drug development strategies in immunology

Published

on

While agents like AbbVie’s Humira have transformed the treatment landscape, not all patients benefit equally from the drug. Better biomarker analysis and more investment in mechanistic trials can inform the development of more effective therapies with broader clinical value.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version